$8.02
0.38% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Stock price

$7.99
-2.58 24.41% 1M
-5.88 42.39% 6M
-3.04 27.56% YTD
-0.18 2.20% 1Y
-11.51 59.03% 3Y
-14.80 64.94% 5Y
-10.01 55.61% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.28 3.39%
ISIN
US86150R1077
Symbol
STOK

Key metrics

Market capitalization $423.21m
Enterprise Value $189.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.30
P/S ratio (TTM) P/S ratio 25.28
P/B ratio (TTM) P/B ratio 1.82
Revenue growth (TTM) Revenue growth 81.04%
Revenue (TTM) Revenue $16.74m
EBIT (operating result TTM) EBIT $-117.30m
Free Cash Flow (TTM) Free Cash Flow $-84.70m
Cash position $239.28m
EPS (TTM) EPS $-2.10
P/E forward negative
P/S forward 23.61
EV/Sales forward 10.56
Short interest 25.33%
Show more

Is Stoke Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Stoke Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Stoke Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Stoke Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Stoke Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
17 17
81% 81%
100%
- Direct Costs 4.55 4.55
3% 3%
27%
12 12
166% 166%
73%
- Selling and Administrative Expenses 40 40
20% 20%
237%
- Research and Development Expense 85 85
8% 8%
509%
-113 -113
5% 5%
-674%
- Depreciation and Amortization 4.55 4.55
3% 3%
27%
EBIT (Operating Income) EBIT -117 -117
4% 4%
-701%
Net Profit -105 -105
2% 2%
-630%

In millions USD.

Don't miss a Thing! We will send you all news about Stoke Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stoke Therapeutics Inc Stock News

Neutral
Business Wire
2 days ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Wednesday, March 5, 2025 Time: 9:50 a.m. ET Leerink Partners ...
Positive
Market Watch
10 days ago
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Neutral
Business Wire
10 days ago
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevuners...
More Stoke Therapeutics Inc News

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Head office United States
CEO Edward Kaye
Employees 110
Founded 2014
Website www.stoketherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today